Company logo

LXRX - Lexicon Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
The Woodlands, United States

LXRX price evolution
LXRX
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Current assets
Cash $59.52 $64.06 $92.12 $89.89
Short term investments $26.98 $22.68 $28.8 $28.61
Net receivables $0.04 $0.01 $0.02 $0.16
Inventory
Total current assets $88.43 $88.92 $124 $123.26
Long term investments
Property, plant & equipment $1.14 $1.18 $1.31 $1.2
Goodwill & intangible assets $44.54 $44.54 $44.54 $44.54
Total noncurrent assets $47.75 $47.99 $48.33 $48.41
Total investments $26.98 $22.68 $28.8 $28.61
Total assets $136.18 $136.91 $172.33 $171.67
Current liabilities
Accounts payable $9.32 $9.15 $8.35 $8.54
Deferred revenue
Short long term debt $11.69 $11.68
Total current liabilities $18.91 $22.12 $34.25 $32.81
Long term debt $23.48
Total noncurrent liabilities $24.57 $1.19 $1.48 $1.62
Total debt $23.48 $11.69 $11.68
Total liabilities $43.48 $23.31 $35.73 $34.44
Shareholders' equity
Retained earnings -$1511.25 -$1487.78 -$1462.16 -$1439.04
Other shareholder equity -$0.04 -$0.01 -$0.01 -$0.01
Total shareholder equity $92.7 $113.59 $136.6 $137.23
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $64.06 $126.26 $36.11 $80.39
Short term investments $22.68 $26.01 $235.55 $79.67
Net receivables $0.01 $0.4 $56.53 $5.92
Inventory $4.24 $4.68
Total current assets $88.92 $157.72 $337.75 $173.32
Long term investments
Property, plant & equipment $1.18 $0.29 $14.05 $15.87
Goodwill & intangible assets $44.54 $44.54 $64.26 $94.66
Total noncurrent assets $47.99 $46.07 $79.96 $110.81
Total investments $22.68 $26.01 $235.55 $79.67
Total assets $136.91 $203.79 $417.71 $284.14
Current liabilities
Accounts payable $9.15 $5.47 $12.18 $17.76
Deferred revenue $27.05
Short long term debt $11.65 $11.01 $1.11
Total current liabilities $22.12 $46.81 $65.34 $36.75
Long term debt $234.17 $243.89
Total noncurrent liabilities $1.19 $0.61 $235.27 $273.79
Total debt $11.65 $245.18 $245
Total liabilities $23.31 $47.42 $300.61 $310.54
Shareholders' equity
Retained earnings -$1487.78 -$1400.02 -$1341.44 -$1471.58
Other shareholder equity -$0.01 -$0.01 $0.08 -$0.01
Total shareholder equity $113.59 $156.37 $117.1 -$26.41
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Revenue
Total revenue $0.04 $0.01 $0.02 $0.23
Cost of revenue
Gross Profit $0.04 $0.01 $0.02 $0.23
Operating activities
Research & development $14.93 $16.5 $15.68 $10.26
Selling, general & administrative $8.49 $8.85 $7.3 $7.94
Total operating expenses $23.42 $25.34 $22.98 $18.19
Operating income -$23.38 -$25.33 -$22.96 -$17.96
Income from continuing operations
EBIT -$23.37 -$25.32 -$22.95 -$17.9
Income tax expense
Interest expense $0.11 $0.29 $0.17 $0.17
Net income
Net income -$23.48 -$25.61 -$23.12 -$18.07
Income (for common shares) -$23.48 -$25.61 -$23.12 -$18.07
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $0.3 $24 $322.07 $63.21
Cost of revenue $1.93 $3.23 $2.49
Gross Profit $0.3 $22.07 $318.84 $60.72
Operating activities
Research & development $55.05 $153.62 $91.92 $100.24
Selling, general & administrative $32.34 $47.23 $56.84 $63.75
Total operating expenses $87.39 $69.87 $177.4 $164
Operating income -$87.09 -$47.8 $141.44 -$103.28
Income from continuing operations
EBIT -$86.96 -$44.03 $144.79 -$99.77
Income tax expense -$6.01
Interest expense $0.8 $14.54 $20.68 $20.78
Net income
Net income -$87.76 -$58.57 $130.13 -$120.55
Income (for common shares) -$87.76 -$58.57 $130.13 -$120.55
(in millions $) 31 Mar 2022 31 Dec 2021 30 Sep 2021 30 Jun 2021
Net income -$23.48 -$25.61 -$23.12 -$18.07
Operating activities
Depreciation $0.11 $0.11 $0.1 $0.04
Business acquisitions & disposals
Stock-based compensation $2.77 $2.23 $2.71 $2.79
Total cash flows from operations -$23.42 -$22.83 -$17.15 -$21.88
Investing activities
Capital expenditures -$0.08 -$0.02 -$0.21 -$0.95
Investments -$4.33 $6.12 -$0.19 $15.09
Total cash flows from investing -$4.41 $6.1 -$0.4 $14.14
Financing activities
Dividends paid
Sale and purchase of stock -$0.86 $0.38 $19.78 -$0.02
Net borrowings $24.15 -$11.7
Total cash flows from financing $23.28 -$11.32 $19.78 -$0.02
Effect of exchange rate
Change in cash and equivalents -$4.54 -$28.05 $2.23 -$7.76
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$87.76 -$58.57 $130.13 -$120.55
Operating activities
Depreciation $0.29 $2.93 $3.65 $3.68
Business acquisitions & disposals $160.38
Stock-based compensation $10.58 $13.27 $14.22 $11.7
Total cash flows from operations -$87.02 -$142.97 $113.81 -$148.61
Investing activities
Capital expenditures -$1.22 $10.93 -$0.07 -$0.1
Investments $3.33 $209.44 -$155.78 $169.67
Total cash flows from investing $2.11 $380.76 -$155.85 $169.58
Financing activities
Dividends paid
Sale and purchase of stock $34.41 $68.94 -$0.94 -$0.24
Net borrowings -$11.7 -$216.58 -$1.28 -$2
Total cash flows from financing $22.71 -$147.64 -$2.23 -$2.24
Effect of exchange rate
Change in cash and equivalents -$62.2 $90.15 -$44.27 $18.73
Fundamentals
Market cap $290.20M
Enterprise value $254.16M
Shares outstanding 149.59M
Revenue $308.00K
EBITDA -$89.17M
EBIT -$89.53M
Net Income -$90.28M
Revenue Q/Q 37.04%
Revenue Y/Y -98.08%
P/E ratio -3.21
EV/Sales 825.20
EV/EBITDA -2.85
EV/EBIT -2.84
P/S ratio 942.22
P/B ratio 3.13
Book/Share 0.62
Cash/Share 0.40
EPS -$0.60
ROA -58.52%
ROE -75.21%
Debt/Equity 0.21
Net debt/EBITDA 0.18
Current ratio 4.68
Quick ratio 4.68